Please login to the form below

Not currently logged in
Email:
Password:

cell and gene therapies

This page shows the latest cell and gene therapies news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

Gottlieb also promises to speed biosimilars and cell and gene therapies in 2019. ... as developing regulatory pathways for cell and gene therapies.

Latest news

  • Novartis buys CellforCure to bolster cell, gene therapy Novartis buys CellforCure to bolster cell, gene therapy

    It says the deal would “would bolster CAR-T cell therapy manufacturing capacity with potential to expand to other cell and gene therapies in Novartis pipeline.”. ... Under the terms of the deal, CellforCure will become a wholly-owned Novartis

  • Digital tech from Autolus and Oxford BioMedica to speed advanced therapies Digital tech from Autolus and Oxford BioMedica to speed advanced therapies

    Technical barriers to manufacturing cell and gene therapies and creating an entirely new integrated supply chain all the way to the patient (or from the patient and back, in the case ... A network of Advanced Therapy Treatment Centres has been set up

  • MedCity sets up advanced therapy research network MedCity sets up advanced therapy research network

    cell, tissue and gene therapies. ... The government-funded Cell and Gene Therapy Catapult is currently building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market, and is working on

  • Novartis: pipeline will generate 60 filings in three years Novartis: pipeline will generate 60 filings in three years

    to 2021 across its drug, cell and gene therapy platforms. ... Advanced therapy medicinal products. Novartis’ push into advanced therapy medicinal products (ATMP) such as cell and gene therapies means it now has 13 candidates in clinical development

  • CHMP backs Spark’s Luxturna, but rejects Sarepta again CHMP backs Spark’s Luxturna, but rejects Sarepta again

    The EMA’s advisory committee recommended approval of Luxturna (voretigene neparvovec), for the treatment of adults and children suffering from inherited retinal dystrophy (IRD) caused by RPE65 gene mutations, a rare ... Once approved, Luxturna will be

More from news
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Gene and cell therapies, novel approaches to rare disease and drug replacements, like digital therapies, are about to crowd the market, creating gaps in education for physician and payer alike. ... an inflection point and quickly started a steep climb to

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and ... This involves incorporating new diagnostic

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Cell and gene therapies are not just revolutionising clinical outcomes, but also in how healthcare systems administer treatment to patients, and how those healthcare systems will pay for them. ... Cell and gene therapies undoubtedly do pose difficult

  • No incentive for a cure No incentive for a cure

    Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... And it is a revolution. that is happening right now; there are many such therapies in company pipelines, several of

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting,” says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Abeona Therapeutics appoints new additions to board of directors Abeona Therapeutics appoints new additions to board of directors

    Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and gene therapies for Novartis subsidiaries Systemix Inc.

  • Paul Blake joins Oxford BioMedica Paul Blake joins Oxford BioMedica

    He will head the clinical development of the company's pipeline of gene and cell therapies. ... therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from

  • Life at the end of the Brexit tunnel

    An Advanced Therapies Treatment Centre to develop cell and gene therapies. ... Expansion of the Cell and Gene Therapy Manufacturing Centre in Stevenage.

  • Introduction to the manufacturing of biologics

    However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins or  ... polypeptides.  Examples of biologics  include blood or blood

  • The Clinical Trial Company

    The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market. ... TCTC are experts in advanced therapies, such as cell and gene therapies, as well as orphan drug and biologics.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...
NHS Long Term Plan - Digital is firmly on the agenda. Are you ready?
The message is clear. To keep pace with the NHS, pharma and healthcare companies must act now and refine their digital strategy to meet the needs of a transforming NHS....

Infographics